Molecular Imaging

Scientists at Erasmus University release new data on molecular imaging

Published in Clinical Oncology Week, July 30th, 2007

According to recent research published in the journal Cancer Biotherapy and Radiopharmaceuticals, "In peptide receptor radionuclide therapy (PRRT), the dose-limiting organ is, most often, the kidney. However, the precise mechanism as well,as the exact localization of kidney damage during PRRT have not been fully elucidated."

"We studied renal damage in rats after therapy with different amounts Of [Lu-177- DOTA(0),Tyr(3)]octreotate and investigated Tc-99m-DMSA (dimercaptosuccinic acid) as a tool to quantify renal damage after PRRT. Experimental Twenty-nine (29) rats were divided into 3 groups and injected with either 0,278, or 555 MBq...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week

Source: Clinical Oncology Week (2007-07-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry